PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

An “immunogenic composition” is not a vaccine (T 0070/23)

  • Technology: Biotechnology
  • 8th August 2025
While G1/24 mandates consulting the description, T 0070/23 is a crucial reminder of its limits. The case shows how the Board of Appeal refused to let a description definition override the clear technical meaning of a product claim.
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.

Originally posted on IPKat.

In the recent Board of Appeal decision T 0070/23, GSK argued that its “immunogenic composition” product claim should be interpreted as limited by its efficacy as a vaccine, particularly in view of a description definition of the term. However, the Board of Appeal found both that product claims should not be interpreted as comprising therapeutic effects and that the description definitions do not override clear claim language. Whilst decided before G1/24, the decision is entirely aligned with recent interpretations of G1/24 by Boards of Appeal.

Legal background: Claim construction

The assessment of inventive step under Article 56 EPC is highly dependent on the objective technical problem, which is itself derived from the technical effect of the features distinguishing the invention from the closest prior art. It is therefore no surprise that patentees, when faced with a sticky inventive step objection, may argue for a claim construction that imports a technical effect from the description, such as therapeutic efficacy.

However, the case law of the Boards of Appeal has long warned against using the description to read limitations into a claim that has a clear technical meaning, especially with respect to product claims. As confirmed by the recent interpretations of the landmark EBA decision G1/24 on claim interpretation, the description cannot be used to give a different meaning to features in a claim, which themselves impart a clear, credible technical teaching to the skilled reader. Additionally, if a therapeutic effect is intended to be a limiting feature of the claim, the established approach is to use the purpose-limited product claim format under Article 54(5) EPC (although notably, this is the complete opposite of the UK approach to claim construction of medical use claims). 

Case background

The case in T 0070/23 related to EP 2903638 (GSK). The patent concerned immunogenic compositions derived from the capsular saccharides of Streptococcus agalactiae, also known as ‘group B streptococcus’, or ‘GBS’. The patent was opposed by Pfizer. Claim 1 of the main request was directed to “an immunogenic composition” comprising a cocktail of five different capsular saccharides from different GBS serotypes (Ia, Ib, II, III, and V) conjugated to a carrier protein. The claim specified “an immunogenic composition” but there was no dispute that the claim was a product claim, not a second medical use claim (r. 3). 

Claim versus description 

The main issue on appeal was inventive step, with the entire case hinging on the construction of the term “immunogenic composition”. GSK argued that the term “immunogenic” was a functional feature.  GSK additionally submitted that, when read in conjunction with the description, the term implied efficacy as a vaccine. 

The description included the following boilerplate paragraph: 

“Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen(s), as well as any other components, as needed. By ‘immunologically effective amount’, it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. Commonly, the desired result is the production of an antigen (e.g., pathogen)-specific immune response that is capable of or contributes to protecting the subject against the pathogen. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non-human primate, primate, etc.), the capacity of the individual’s immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor’s assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.“

According to GSK, the only technically sensible way of reading the claim in view of this description definition was to regard each constituent of the composition as having a protective/prophylactic effect.

Pfizer, on the other hand, submitted that given the claimed subject-matter was a product per se, it should not be defined or limited by its therapeutic efficacy. Pfizer further argued that it was established case law that the description should not be taken into account when construing claims that are clear on their own. 

The Board of Appeal agreed with Pfizer. Citing T 932/99 and T 1018/02, the Board of Appeal found that the claim was not drafted as a purpose-limited product claim under Article 54(5) EPC, meaning that a therapeutic purpose or effect was not a feature of the claim. Additionally, for the Board of Appeal, the claim should further not be read as including the functional features set out in the description. The Board of Appeal further noted that, even if the description was considered, the cited paragraph only provided a general explanation of immunogenic compositions used as vaccines and not a definition of all compositions falling within the scope of the claim (presumably therefore, GSK would also have had issues trying to use this paragraph as basis for a more defined functional definition of the composition’s effect). 

The Board of Appeal therefore interpreted “immunogenic composition” as used in the claims as a composition suitable for raising an immune response to at least one of the immunogens contained in it, wherein the level of protection against a specific disease should not be considered a feature of the claim (r. 11). 

An obvious alternative

In view of the Board of Appeal’s claim construction, the technical effect for inventive step analysis was formulated simply as a composition that remained immunogenic. The objective technical problem was considered to be the mere provision of a further alternative immunogenic composition. The question then became whether the skilled person, starting from the prior art, would have arrived at the claimed composition to solve this problem. The Board of Appeal found that they would have in view of a direct suggestion in the prior art document that clearly presented the skilled reader with two arbitrary alternatives. The claimed composition was therefore found to lack an inventive step, and the patent was revoked. 

GSK tried to rescue the patent with an auxiliary request that defined the composition as “a vaccine”, however this was not admitted for being late filed. The Board of Appeal considered that this amendment would not have overcome the issue as, even with the new wording, “a protective immune response against all of GBS serotypes present in the vaccine” would still not be considered a feature of the claim. 

Relevance to G1/24

This case was decided before the decision in G1/24 was issued. However, interestingly, given what it considered the established case law on functional description definitions, the Board of Appeal did not find that its decision depended on any nuances that might have arisen from G 1/24. Whilst G 1/24 found that the description must always be “consulted”, this is not being interpreted by Boards of Appeal as giving patentees a free pass to use the description to rewrite the claims. 

The Board of Appeal in the present case, whilst deciding before the G 1/24 decision was issued, was thus entirely in line with how G1/24 has been interpreted. However, like the cases to apply G1/24, this case related to the relevance of a potentially narrowing definition in the description. We wait to see how the Boards of Appeal will respond to use of potentially broadening description definitions, such as in the referring case to G1/24, oral proceedings for which are scheduled for the end of this year (EP3076804).

Analysis

The decision in T 0070/23 is a clear reminder of the fundamental principle of patent law, emphasised recently in G1/24, that the claims define the scope of protection. This decision is also reminiscent of T 1924/20, in which the Board of Appeal similarly refused to import functional features from the description into the claims. It is common for claimed inventions in the pharmaceutical field to include a functional definition in the preamble of the claim, e.g. “a therapeutic composition”. T 0070/23 implies that these types of limitations in a product claim may be considered fundamentally meaningless by the EPO, whilst also potentially leading to difficulties of enforcement. T 0070/23 is also another reminder of the general pointlessness of boilerplate language, at least in EPO proceedings.  The advice remains: the best way to limit a claim is in the claims, not the description.  

At Evolve, we are experts in IP strategy. Do you need advice on how to protect your pharma or biotech innovation? We would love to hear from you: Contact us.

Subscribe to Evolve Insights.

Further Evolve Insights

  • Construing the claims to include technical effects mentioned in the description (T 1924/20)
  • UK divergence from the EPO on plausibility (Sandoz v BMS), Part 1: Is the “plausibility” test the same for both sufficiency and inventive step? 
  • Beware of boilerplate: Practical lessons for patent drafting from G1/24 (Claim interpretation)
  • First interpretation of G 1/24 (the description must always be consulted) (T 1561/23)
  • G 1/24 in the spotlight: Description definitions do not override clear claim language (T 1999/23) 

Related insights...

Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

  • 3rd November 2026
Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure. The recent decision in T 0251/25 nonetheless found Boehringer Ingelheim’s…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Reformatio in peius survives a procedural violation (T 1168/24)

  • 2nd November 2026
Sometimes patent law is about procedures and not inventions. The appeal in T 1168/24 related to the lipid nanoparticle (LNP) technology behind the COVID-19 vaccines, opposed by Merck and Moderna. After two rounds of opposition and two appeals, the patent was revoked for added matter. Whilst the global litigation surrounding LNPs is interesting in its…
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, the Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Patenting the use of medical devices (T 0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter

  • 6th May 2026
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice